Claims

1. A polypeptide, or a pharmaceutically acceptable salt thereof, comprising the amino acid sequence selected from the group consisting of:

K(γE-C18diacid)K[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 15),

K(γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 16),

K(O2Oc-O2Oc-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 17),

K(γE-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 18).

2. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

K(γE-C18diacid)K[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 15).

3. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

K(γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 16).

4. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

K(O2Oc-O2Oc-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 17).

5. The polypeptide, or pharmaceutically acceptable salt thereof, comprising the amino acid sequence

K(γE-γE-C18diacid)[CNTATC]ATQRLANFLRHSSNN(αMePhe)GPILPPTEVGSNTY-amide (SEQ ID NO: 18).

6. A pharmaceutical composition comprising the polypeptide or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable excipient.

7. A kit comprising the polypeptide or pharmaceutically acceptable salt of claim 1, optionally further comprising instructions for use.